EQUITY IDEAS

5 Companies which reduced maximum Debt in FY24 1. Indian Hotels 2. Balaji Amines 3. Dr Lal Pathlabs 4. Avantel 5. Cyient All the above companies have reduced debt by more than 50% in just one year

Blue Star has reduced its debt by almost 65% in last 1 year. Johnson Controls-Hitachi has reduced its debt by almost 75% in last 1 year.

SEBI to increase Minimum Subscription Lot size in SME to ₹5 lakhs , to decrease crazy retail participation Source: The Hindu Business line 🤧🤧

Quarterly updates must be tracked to monitor the progress.

📮*List of 30+ Companies where management have guided to deliver 15-40 % Growth🔥* All stocks must be on radar 🔸Indo count Industries - REV Guidance: 20-25% - Double the Revenue in the Next 3-4 Years - Margin : 16 - 18% - Volume guidance: 110-115 Mn Mtrs 🔸Welspun Living: - FY25 REV Growth: 10-12 % (Conservative side) - Margins : 15.5-16.5 % - ROCE - 16 % - Home Textile Business 10-12 % growth - Emerging Business 30 % growth - Flooring Business Margins 10-12 % - Aspirations of 15,000 Cr Revenue by 2026-27 🔸JustDial: - FY25 REV guidance - 15% growth - Margin expansion may continue - EBITDA margins may inch to 27-28% - Net Cash on B/S 4600 Cr+ 🔸Hariom Pipes - REV FY 26 - 2500 Cr. - 40% CAGR + with improvement in Margins - FCF positive - De Leveraging plans 🔸Carysil - FY25: REV Guidance: 1000 Cr - Including Inorganic Expansion - Margin Guidance: 18-20 % 🔸Medi Assist - Maintain Industry level growth of 23-25% - Margins will improve as synergy kicks in 🔸Supriya Lifescience - 20-25% revenue growth. - 1000 Cr Topline by FY27. - Margins of 28-30%. 🔸Shankara - REV Growth 20-25 % CAGR - Long Term guidance : 10,000 Cr - Demerger to create value. - Return ratio will improve. - Margins will expand as non-steel mix increases 🔸Nuvama Wealth: - WM & AM will be 75-80 % of earnings - RM to double in 3-5 years - Grow ARR & Asset Income - In 5 Years grow client & client assets 2-2.5 x - Operating Leverage will drive profitability 🔸Indigo Paints - 3-4 X Industry growth rates - 15-30 % REV growth depending upon Industry growth rates - Industry leading gross margins to be maintained at 48-49% - EBITDA margins to grow by 50-100 basis points in FY25 🔸Dhabriya Polywood - REV Guidance 25 % for next few years - Orderbook 140 Cr - ROCE will improve 🔸Lumax Auto: - 20-25 % REV growth - 14-15 % Margins 🔸Muthoot Finance: - 15 %+ growth - 18-20 % growth in non gold loan AUM - 150-200 branch addition 🔸EMS: - 35 % REV Growth - Margins to be maintained 🔸Jash: - 30 % REV growth for FY25 - 1000 Cr REV by FY28 - EBITDA Margins 22-25 % 🔸IKIO Lighting: - REV Growth 20-25 % - EBITDA Margins 20-22 % 🔸Manappuram Finance: - 15 %+ AUM growth - 20 % ROE 🔸Vaibhav Global: - 14-17 % Revenue Growth - Margins Expansion in the next few years - Operating Leverage will drive Profitability 🔸Star Health ~ GWP: 15,251 Cr --> 30,000 Cr (20% CAGR) ~ PAT: 845 Cr --> 2500 Cr (3 x) ~ Market Share Expansion 33 % ~ 35% 🔸Rategain: - 20 % Organic Growth + Inorganic Expansion - Double Revenue in 3 Years - 2000 Cr (25 % CAGR) - E FY27: EBITDA 500 Cr (Margins 25 %) - Holds over 1000 Cr in B/S 🔸GoodLuck India: - 15-20 % growth with margin expansion. - Revenue Guidance: 4000 Cr for FY25 4500 Cr for FY26 - Defence will be additional contributor from FY25 🔸Krsnaa Diagnostics: - 25-30% Revenue growth. - 25-26% Margins. 🔸Rushil Decor: FY24 : REV : 844 Cr 5 Year Guidance - REV 2500 Cr (3 X) FY25 : Guidance - REV - 1,000 Cr🔼19 % - EBITDA Margins - 14-16 % 🔸IDFC First Bank: FY25 - Deposit growth 30 % - loan book growth 22-23 % - Credit Cost 1.6 % Long Term Guidance ~ Deposits: Growth outlook of 25% ~ Advances: Growth outlook of 20% ~ Asset Quality: GNPA - 1.5%, NNPA - 0.4% ~ Return Ratio: ROA - 2%, ROE - 18% 🔸Glenmark Lifescience: ~ Mid - Teens Growth ~ Margins 28-30 % ~ CDMO to double by 2027 🔸SG MART SG Mart – Tech Enabled B2B marketplace for Construction Materials ~ E REV FY27: 18,000 Cr FY24: - REV: 2683 Cr - PAT: 61 Cr 🔸Cantabil Retail ~ REV : 1000 Cr by Mid FY27 (20 % CAGR) ~ EBITDA Margins : 28-30 % If SSSG Growth 6-8 % is back 🔸Satin Creditcare: - AUM & Disbursement growth - 25% - Credit Cost for FY25 to be in the range of 1.5-1.75% - NIM's - 12.25-12.75 % - ROA - 4.25-4.75 % 🔸PI Industries: ~ 15 %+ REV growth ~ Pharma Business Scale up 🔸Yatharth Hospital: ~ Double bed capacity in the next 3-4 years ~ Increase APROB & Occupancy ~ 1 Acquisition per year 🔸KEI Industries: Long term guidance ~ 15-17 % growth for the next few years ~ 100-150 bps margins improvement ~ 11 % EBITDA margins

*📮TCS Concall Update* Outlook - Long term Positive • Order book came in at $8.3 bn in Q1FY25. QoQ $13.2 bn, YoY $10.2 bn. Some of the orders got pushed forward by some weeks. Deal pipeline is strong. • Dollar Revenues grew 4.4% cc yoy to $ 7505 for Q1FY25. This was ahead of expectations. • EBIT Margins came in at 24.7%, ahead of expectations. • Employee count has increased for the first time in the past three quarters. *Outlook by the Company:* A. FY25 to be better than FY24 since seeing broad based growth across all geographies. B. Pricing is stable and realisations are improving. C. Margins aim is for 26-28%. This is possible through pricing improvement. D. No material change in customer behaviour. Stock is trading at a P/E of 26x FY26E Earnings and long-term outlook remains positive.

https://srikavimoney.blogspot.com/2024/05/reaching-realistic-guide-to-crorepati.html THE POWER OF TOP UP SIP CAN MAKE YOU CROREPATI!

Photo from Srikanth Matrubai

Photo from Srikanth Matrubai